InsiderTrades.com logo
William Grossman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

William Grossman Biography and Net Worth

Interim Chief Medical Officer of enGene

William Grossman, M.D., Ph.D., a member of enGene’s Board of Directors, assumed the role of interim Chief Medical Officer in June 2026. He is the former Senior Vice President and Therapeutic Area Head of Oncology Clinical Development at Gilead Sciences Inc. where he oversaw the oncology portfolio (early and late-stage clinical development) and collaboration programs. Prior to that, he held several Chief Medical Officer roles including at Arcus Biosciences and Bellicum Pharmaceuticals. He has held additional leadership roles at Genentech/Roche, Merck, AbbVie, and Biothera. Dr. Grossman received his M.D. and Ph.D. in Immunology from Washington University School of Medicine’s Medical Scientist Training Program and completed his medical and post-doctoral training in both the Divisions of Pediatrics and Medicine at Washington University School of Medicine. He also currently serves on several advisory boards and will continue to serve on enGene’s Board of Directors as a non-independent Director during his interim CMO role.

What is William Grossman's net worth?

The estimated net worth of William Grossman is at least $9.80 thousand as of September 22nd, 2026. Dr. Grossman owns 5,102 shares of enGene stock worth more than $9,796 as of September 25th. This net worth estimate does not reflect any other investments that Dr. Grossman may own. Learn More about William Grossman's net worth.

How do I contact William Grossman?

The corporate mailing address for Dr. Grossman and other enGene executives is 4868 Rue Levy, Suite 220, Saint-laurent. enGene can also be reached via phone at (514) 332-4888 and via email at [email protected]. Learn More on William Grossman's contact information.

Has William Grossman been buying or selling shares of enGene?

Within the last three months, William Grossman has bought $10,050.94 of enGene stock. Most recently, on Tuesday, September 22nd, William Grossman bought 5,102 shares of enGene stock. The stock was acquired at an average cost of $1.97 per share, with a total value of $10,050.94. Following the completion of the transaction, the insider now directly owns 5,102 shares of the company's stock, valued at $10,050.94. Learn More on William Grossman's trading history.

Who are enGene's active insiders?

enGene's insider roster includes Harold Cooper (CEO), and William Grossman (Interim Chief Medical Officer). Learn More on enGene's active insiders.

Are insiders buying or selling shares of enGene?

During the last year, enGene insiders bought shares 1 times. They purchased a total of 5,102 shares worth more than $10,050.94. The most recent insider tranaction occured on September, 22nd when insider William Grossman bought 5,102 shares worth more than $10,050.94. Insiders at enGene own 10.5% of the company. Learn More about insider trades at enGene.

Information on this page was last updated on 9/22/2026.

William Grossman Insider Trading History at enGene

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/22/2026Buy5,102$1.97$10,050.945,102View SEC Filing Icon  
See Full Table

William Grossman Buying and Selling Activity at enGene

This chart shows William Grossman's buying and selling at enGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

enGene Company Overview

enGene logo
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More

Today's Range

Now: $1.93
Low: $1.91
High: $1.95

50 Day Range

MA: $1.83
Low: $1.69
High: $2.05

2 Week Range

Now: $1.93
Low: $1.40
High: $12.25

Volume

1,315,948 shs

Average Volume

979,263 shs

Market Capitalization

$129.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A